Solventum had its Relative Strength (RS) Rating upgraded from 78 to 83 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Solventum is building a with an 85.92 entry. See if the stock can break out in volume at least 40% above average.
Earnings growth dropped in the most recent quarter from -35% to -36%. But revenue gains moved higher, from 2% to 3%.
The company holds the No. 29 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and TransMedics Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
